Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 10, 2025 /PRNewswire/ -- Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human evaluation of its FieldForce™ Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).

Read the full press release here.

Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025

CARDIFF-BY-THE-SEA, Calif., and PHILADELPHIA, Oct. 9, 2025 /PRNewswire/ —Field Medical, Inc., a leader in pulsed field ablation (PFA) technology for ventricular tachycardia (VT), today announced its participation at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium), taking place Oct. 10–11 in Philadelphia..

Read the full press release here.

Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform

CARDIFF-BY-THE-SEA, Calif., [July 1, 2025] /PRNewswire/ — Field Medical, Inc., a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, today announced the close of a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors.

Read the full press release here.